Baiyunshan amoxicillin capsule passed the consistency evaluation

On July 12, Baiyunshan issued an announcement stating that the branch Guangzhou Baiyunshan Pharmaceutical Group Co.

The amoxicillin capsule of Baiyunshan Pharmaceutical General Factory was officially launched in China in August 2006, and the consistency evaluation application was submitted to the National Medical Products Administration on November 4, 2018, and it was accepted on November 12, 2018

Amoxicillin is a semi-synthetic penicillin antibiotic, used for the following infections caused by sensitive bacteria (strains that do not produce β-lactamase): Otitis media and sinusitis caused by Streptococcus hemolyticus, Streptococcus pneumoniae, Staphylococcus or Haemophilus influenzae , Pharyngitis, tonsillitis and other upper respiratory tract infections; genitourinary tract infections caused by Escherichia coli, Proteus mirabilis or Enterococcus faecalis; skin and soft tissue infections caused by Streptococcus hemolyticus, Staphylococcus or Escherichia coli; hemolytic chain aureus, Streptococcus pneumoniae, Haemophilus influenzae, or Staphylococcus aureus caused by acute bronchitis, pneumonia and other respiratory tract infections; acute uncomplicated gonorrhea and so on

Currently in China listed amoxicillin capsule manufacturers also include Zhuhai United Laboratories Co.

According to data from Minai.

As of the date of this announcement, Baiyunshan Pharmaceutical General Factory has invested approximately RMB 7.